Plasticizer Exposure and Its Consequences on Health

NCT ID: NCT06512298

Last Updated: 2024-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Plasticizers are chemicals commonly found in many everyday items, from food packaging to medical equipment. Although they are pervasive in our daily lives, researchers still don't have a clear picture of their long-term effects on human health. Evidence suggests that these substances might disrupt various biological functions such as the immune system, the balance of gut bacteria, hormone regulation, and brain processes. While some studies have linked plasticizer exposure to health issues, definitive data from human studies are still lacking.

The PEACH study aims to bridge these knowledge gaps by investigating how plasticizers affect human health. The study focuses on understanding how these chemicals are absorbed, distributed, and accumulated in the body across different groups of patients. The investigators are particularly interested in how plasticizers influence gut microbiota and the functionality of immune cells, as well as their effects on neurotransmitters involved in brain function.

A combination of patient data, systems biology, and laboratory models will be used to thoroughly assess the biological impacts of plasticizers. Advanced techniques such as mass spectrometry will aid in studying toxicokinetic properties, sequencing technologies will be used to examine immune effects, and radiouptake assays will be employed to explore interactions with neurotransmitter transport. This comprehensive methodology will provide new insights into the effects of both short-term and long-term exposure to plasticizers.

The PEACH study introduces innovative methods to the field, aiming to create a robust model for understanding how plasticizer compounds behave in the human body. It employs state-of-the-art techniques to assess the dynamics of these chemicals, marking a significant advancement in environmental health research.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Wider research context: Industrial plasticizers are ubiquitous in modern society, utilized in products ranging from food packaging to medical supplies. Despite their widespread use, the health implications of chronic plasticizer exposure in humans remain inadequately understood. These substances potentially interfere and disrupt various biological processes, including immune activity, gut microbiota balance, endocrinological function, and neurophysiological health. Current epidemiological or exposure studies were able to pinpoint clinical associations with plasticizer exposures, but conclusive mechanistic human in vivo data are missing.

Research questions: The PEACH study is designed to fill critical gaps in the understanding of the biological implications of plasticizer exposure. The investigators aim to analyse the pharmacokinetics of plasticizers in different patient cohorts and elucidate their bioaccumulation, distribution, and metabolism. Thereby, the interplay between plasticizer exposure and metabolism, gut microbiota composition and immune cell functionality will be explored. Furthermore, the impact of plasticizer exposure on neurotransmitter physiology will be elucidated.

Approach: The study employs a comprehensive methodology that integrates the findings from clinical cohorts, systems biology approaches, and in vitro models. Three distinct work packages will examine pharmacokinetic properties via mass spectrometry, study immunological effects through advanced sequencing technologies \& phenotypization, and investigate pharmacodynamic interactions with neurotransmitter transporters using human in-vitro assays. Longitudinal sampling from acute and chronic exposure cohorts will offer an evolving perspective on effects of plasticizer exposure.

Level of originality: The PEACH study introduces groundbreaking methodologies and scope to the investigation of plasticizer exposure. It aims to support the scientific community with first human in-vivo pharmacokinetic models for these compounds while utilizing high-throughput techniques for pharmacodynamic assessment, marking a notable advancement in the field.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Beta-thalassemia Glioma Healthy Controls Transfusion-dependent Beta-Thalassemia Intracranial Hemorrhages Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transfusion-dependent thalassemia major (TDTM)

Patients suffering from homozygous transfusion-dependent Thalassemia Major.

No interventions assigned to this group

Thalassemia Minor

Patients suffering from heterozygous transfusion-independent Thalassemia Minor.

No interventions assigned to this group

Healthy controls

Healthy adult controls without any prevalent substance use (nicotine, alcohol etc.).

No interventions assigned to this group

Glioma patients

Adults with high/low-grade glioma, a tumor size \> 3cm that require resection with access to the ventricular system without ventricular hemorrhage.

No interventions assigned to this group

ICU patients

Adults with brain hemorrhage (intracranial, subdural, subarachnoidal), treated with a ventricular shunt.

No interventions assigned to this group

Patients undergoing diagnostic lumbar-puncture (plastic-naive)

Adults that receive a diagnostic lumbar puncture in an outpatient setting.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Exclusion: Plastic implants, chronic infectious disease, pregnancy.

Thalassemia Intermedia/Minor:

* Inclusion: Adult, homozygous/heterozygous ß-Thalassemia Intermedia/Minor
* Exclusion: Plastic implants, chronic infectious disease, pregnancy, transfusion dependency

Healthy adults:

* Inclusion: Adult
* Exclusion: Chronic disease, plastic implants, infectious disease, pregnancy, anemia, medication-, drug-, or alcohol-abuse

Glioma patients:

* Inclusion: Adult, high/low-grade glioma, tumor larger then 3cm, resection with access to the ventricular system
* Exclusion: Large intraventricular hemorrhage, plastic implants, infectious disease

ICU patients:

* Inclusion: Adult, brain hemorrhage, external CSF drain from ventricle
* Exclusion: intraventricular hemorrhage, plastic implants, ECMO, hemodialysis, infectious disease

Patients undergoing diagnostic lumbar-puncture:

* Inclusion: Adult, diagnostic CSF sampling, outpatient setting
* Exclusion: Ventricular hemorrhage, plastic implants, infectious disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Vienna

OTHER

Sponsor Role collaborator

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lukas Wisgrill

Principal Investigator, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Vienna

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lukas Wisgrill, MD, PhD

Role: CONTACT

800-123-4567

Harald Sitte, MD, PhD

Role: CONTACT

800-123-4567

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lukas Wisgrill, MD, PhD

Role: primary

Michael Eigenschink, MD

Role: backup

0043-1-40400-38485

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10.55776/KLP1811624

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

1716/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LI-TASTE Study: Light for Taste
NCT06258096 NOT_YET_RECRUITING NA